Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease
Gorriz, Jose L.
Puchades, María Jesús
Llisterri, José Luis
Pallares Carratalá, Vicente
MetadataShow full item record
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease. There is an increased rate of cardiovascular disease (CVD) in ADPKD. In this study, we evaluate the prevalence of cardiovascular risk factors, the achievement rates for treatment goals and cardiovascular events (CVE) in ADPKD and their relations with asymptomatic CVD in CKD from other etiologies (CKDoe) and controls. Methods: We evaluated 2445 CKD patients (2010–2012). The information collected was: clinical, anthropometric and analytical parameters, treatments and CVD evaluation (intima-media thickness (IMT), atheromatous plaque presence and ankle-brachial index (ABI)). Laboratory, vital status, CVE and hospitalizations were collected for 4 years. Results: ADPKD patients had a worse renal function and worst achievement of blood pressure, higher parathormone levels but lower proteinuria compared to CKDoe. ADPKD patients presented lower IMT values than other groups, however, an intermediate rate of pathologic ABI and atheromatous plaque was present. More than half of the patients received statins, achieving LDL-c levels < 100 only in 50 and 39.8% of them (ADPKD and CKDoe respectively). The number of CVE during the follow-up period was low. In adjusted Cox regression model, ADPDK had the lowest occurrence of CVE of all three groups (HR:0.422, 95%CI 0.221–0.808, p = 0.009). Conclusion: ADPKD patients show intermediate control rates of CVD. A better control of CVD risk seems to be related with a lower load of CVD compared to other groups, which may lead in the long term to a better prognosis. Further investigation is necessary to determine cardiovascular prognosis in ADPKD.
Is part ofBMC Nephrology, 2021, vol. 22, 110
European research projects
The following license files are associated with this item:
Showing items related by title, author, creator and subject.
Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease Anguiano, Lidia; Riera, Marta; Pascual, Julio; Valdivielso Revilla, José Manuel; Barrios, Clara; Betriu i Bars, M. Àngels; Clotet, Sergi; Mojal, Sergi; Fernández i Giráldez, Elvira; Soler, María José (Elsevier, 2016-08-24)Abstract BACKGROUND AND AIMS: Circulating Angiotensin Converting Enzyme 2 (ACE2) activity in chronic kidney disease (CKD) patients without previous history of cardiovascular disease (CVD) has been associated with classical ...
Lorca, Cristina; Mulet, Maria; Arévalo Caro, Catalina; Sánchez, M. Ángeles; Pérez, Ainhoa; Perrino, María; Bach Faig, Anna; Aguilar Martínez, Alicia; Vilella, Elisabet; Gallart-Palau, Xavier; Serra Maqueda, Aida (Taylor & Francis, 2022)Substances with modulatory capabilities on certain aspects of human cognition have been revered as nootropics from the dawn of time. The plant kingdom provides most of the currently available nootropics of natural origin. ...
Usefulness of imaging techniques and novel biomarkers in the prediction of cardiovascular risk in patients with chronic kidney disease in Spain: The NEFRONA project Junyent, Mireia; Martínez Alonso, Montserrat; Borràs, Mercè; Betriu i Bars, M. Àngels; Coll, Blai; Craver Hospital, Lourdes; Marco Mayayo, M. Paz; Sarró, Felipe; Valdivielso Revilla, José Manuel; Fernández i Giráldez, Elvira (Sociedad Española de Nefrologia, 2010)Background: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). Cardiovascular risk assessment in this population is hampered by the failure of ...